

## Ozone at low concentrations does not affect motility and proliferation of cancer cells *in vitro*

Manuela Costanzo,<sup>1</sup> Alessandro Romeo,<sup>2</sup> Barbara Cisterna,<sup>1</sup> Laura Calderan,<sup>1</sup> Paolo Bernardi,<sup>1</sup> Viviana Covi,<sup>3</sup> Gabriele Tabaracci,<sup>3</sup> Manuela Malatesta<sup>1</sup>

<sup>1</sup>Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona

<sup>2</sup>Department of Computer Science, University of Verona

<sup>3</sup>San Rocco Clinic, Montichiari (BS), Italy

### ABSTRACT

Exposure to low ozone concentrations is used in medicine as an adjuvant/complementary treatment for a variety of diseases. The therapeutic potential of low ozone concentrations relies on their capability to increase the nuclear translocation of the Nuclear factor erythroid 2-related factor 2 (Nrf2), thus inducing the transcription of Antioxidant Response Elements (ARE)-driven genes and, through a cascade of events, a general cytoprotective response. However, based on the controversial role of Nrf2 in cancer initiation, progression and resistance to therapies, possible negative effects of ozone therapy may be hypothesised in oncological patients. With the aim to elucidate the possible changes in morphology, migration capability and proliferation of cancer cells following mild ozone exposure, we performed wound healing experiments *in vitro* on HeLa cells treated with low ozone concentrations currently used in the clinical practice. By combining a multimodal microscopy approach (light and fluorescence microscopy, scanning electron microscopy, atomic force microscopy) with morphometric analyses, we demonstrated that, under our experimental conditions, exposure to low ozone concentrations does not alter cytomorphology, motility and proliferation features, thus supporting the notion that ozone therapy should not positively affect tumour cell growth and metastasis.

**Key words:** Wound healing; actin; morphometry; fluorescence microscopy; atomic force microscopy; scanning electron microscopy.

**Correspondence:** Manuela Malatesta, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Strada Le Grazie 8, 37134 Verona, Italy. Tel. +39.045.8027569.

E-mail: [manuela.malatesta@univr.it](mailto:manuela.malatesta@univr.it)

**Contributions:** All authors contributed to the study conception and design. MC, BC, LC, PB performed experiments with the various techniques and analysed data; AR supervised atomic force microscopy experiments and analysed data; VC, GT supervised the project and interpreted data; MM supervised the project, interpreted data and wrote the first draft of the manuscript. All authors read and commented the manuscript, and approved its final version.

**Conflict of interest:** The authors declare no conflict of interest.

**Availability of data and materials:** All data generated or analyzed during this study are included in this published article.

**Ethical Approval:** not applicable.

## Introduction

Oxygen-ozone ( $O_2$ - $O_3$ ) therapy is a modestly invasive practice used in medicine as an adjuvant/complementary treatment for a variety of diseases, and is based on the administration of low  $O_3$  concentrations (reviews in<sup>1,2</sup>). Although the biological mechanisms accounting for the therapeutic effects of  $O_3$  administration have only partially been elucidated, it is known that this highly oxidizing gas acts in a dose-dependent manner.<sup>3,4</sup> High  $O_3$  doses induce a severe oxidative stress resulting in tissue inflammation and damage through the activation of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF- $\kappa$ B); on the contrary, low doses initiate a hormetic response (*i.e.*, “the beneficial effect of a low level exposure to an agent that is harmful at high levels”<sup>5</sup>) leading to a cytoprotective antioxidant response. In particular, the Nuclear factor erythroid 2-related factor 2 (Nrf2), that promotes the transcription of Antioxidant Response Elements (ARE) and the consequent production of antioxidant enzymes,<sup>6</sup> proved to be stimulated by the low  $O_3$  concentrations used for various therapeutic purposes.<sup>7-13</sup> Recently, conclusive evidence has been provided that low  $O_3$  concentration increases the nuclear translocation of Nrf2, thus inducing the Nrf2-mediated Keap1-dependent transcription of ARE-driven genes.<sup>14</sup>

Thus, robust clinical indication and growing scientific data support the efficacy of  $O_3$  therapy in various medical fields such as *e.g.*, orthopedics,<sup>15-17</sup> gastroenterology,<sup>18-20</sup> pneumology,<sup>21,22</sup> dentistry.<sup>23-25</sup> However, doubts persist about potential negative side effects of  $O_3$  administration.

In particular,  $O_3$  therapy is frequently applied to oncological patients due to its efficacy in reducing some adverse side effects of the anti-cancer treatments.<sup>26-30</sup> Possible undesired consequences of  $O_3$  therapy in oncological patients may be hypothesized based on recent findings on the controversial role of Nrf2 in cancer initiation, progression and resistance to therapies. Hyperactivation of Nrf2 may promote tumorigenesis by multiple ways: by helping incipient tumour cells to overcome the oxidative stress, which represents a barrier against neoplastic transformation and cancer initiation;<sup>31</sup> by supporting aberrant cell proliferation through both the induction of a metabolic switch towards anabolic pathways<sup>32</sup> and the modulation of mRNA translation;<sup>33</sup> by promoting angiogenesis<sup>34</sup> and drug resistance<sup>35</sup> through its potent cytoprotective effect.

In fact, no negative effects have so far been reported in oncological patients following  $O_3$  therapy (recent reviews in<sup>36,37</sup>); however, to our knowledge, no experimental data are presently available on the possible changes in morphology, migration capability and proliferation of cancer cells following exposure to low  $O_3$  concentrations.

With the aim to elucidate this issue, we performed wound healing experiments *in vitro*<sup>38</sup> on HeLa cells exposed to the low  $O_3$  concentrations currently used in the clinical practice. A multimodal microscopy and morphometry approach was used to investigate the cytomorphological changes, proliferation and motility of this established cancer cell line that has previously been used as a suitable experimental model to study the effects of the exposure to low  $O_3$  concentrations at the cellular level.<sup>14,39</sup>

## Materials and Methods

### Cell culture, wound healing assay and ozone treatment

HeLa cells were grown in Dulbecco's modified Eagle medium with 10% (v/v) foetal bovine serum (FBS), 1% (w/v) glutamine, 0.5% (v/v) amphotericin B, 100 units/mL of penicillin and 100

$\mu$ g/mL of streptomycin (Gibco), at 37°C in a 5%  $CO_2$  humidified atmosphere. Cells were trypsinized (0.25% trypsin in PBS containing 0.05% EDTA) when subconfluent, and then seeded on glass coverslips in 6-multi-well microplates, for atomic force microscopy (AFM) and scanning electron microscopy (SEM), or in 24-multi-well microplates (for wound healing assay and fluorescence microscopy). For wound healing assay,  $5 \times 10^5$  cells per well were seeded on 24x24 mm slides and, after 48 h, when the cells were confluent, the cell monolayers were scratched with a sterile 200  $\mu$ L pipette tips and immediately exposed to  $O_2$ - $O_3$  gas mixtures at two different  $O_3$  concentrations (10 and 35  $\mu$ g  $O_3$ /mL  $O_2$ ) according to Costanzo *et al.*<sup>40</sup> A single treatment was performed since, in the clinical practice, the  $O_3$  concentrations used for our experiments are administered once or twice a week; however, HeLa cell are rapidly dividing (their cell cycle lasts about 20 h), thus making it impossible to submit the same cells to repeated treatments without causing excessive oxidative stress. The gas was produced by an OZO2 FUTURA apparatus (Alnitec s.r.l., Cremosano, CR, Italy) which generates  $O_3$  from medical-grade  $O_2$ , and allows photometric real-time control of gas flow rate and  $O_3$  concentration. Cells exposed to air under the same experimental conditions served as control. To evaluate cell migration during wound healing, images at 4x magnification were taken at 0 h, 2 h, 6 h and 24 h post-treatment using an inverted microscope (Leica DMIL) equipped with an Optika Microscopes (Ponteranica, BG, Italy) camera: the cell-free area was measured in a total of 12 randomly selected microscope fields per sample (4 fields in 3 independent experiments). The progressive reduction of the cell-free area was expressed as percentage, taking as 100 % the value at time 0.

### Actin staining, and evaluation of the S-phase and mitotic cell fraction

To visualize actin microfilaments, 24 h after scratching the cell monolayers the slides were fixed with 4% (v/v) formaldehyde in PBS (30 min at room temperature, RT) and 70% (v/v) ethanol in water (30 min at -20°C); after rehydration with PBS for 5 min at RT, the slides were incubated with Alexa 488-conjugated phalloidin (Molecular Probes, Invitrogen, Monza, Italy) diluted 1:40 in PBS for 1 h at RT, stained for DNA with Hoechst 33342 (0.1  $\mu$ g/mL in PBS for 10 min), rinsed in PBS, and finally mounted in 1:1 PBS:glycerol.

The percentage of S-phase cells was also assessed 24 h after scratching the cell monolayers: the cells were pulse-labelled with 20  $\mu$ M Bromodeoxyuridine (BrdU, Sigma-Aldrich, St. Louis, MO, USA) for 30 min at 37°C, then fixed with 70% ethanol and incubated for 20 min at RT in 2 N HCl, to denature DNA partially; after neutralization with 0.1 M sodium tetraborate (pH 8.2) for 3 min, samples were washed in PBS, permeabilized for 15 min in PBS containing 0.1 % bovine serum albumin and 0.05 % Tween-20, and incubated for 1 h with a mouse monoclonal antibody recognizing BrdU (BD, Franklin Lakes, NJ, USA) diluted 1:20 in PBS. After two washes with PBS, samples were incubated for 1 h with an Alexafluor 488-conjugated anti-mouse secondary antibody (Molecular Probes, Invitrogen, Milan), diluted 1:200. The cell samples were washed with PBS, stained for DNA with 0.1  $\mu$ g/mL Hoechst 33342 in PBS for 10 min, and finally mounted in PBS:glycerol (1:1). The percentage of BrdU-positive cells was evaluated in the region located within 100  $\mu$ m of the wound edge in 30 randomly-selected fields (40x) per experimental condition. The same microscopic fields were used to evaluate the mitotic index. For observation of all samples, we used an Olympus BX51 microscope equipped with a 100W mercury lamp, under the following conditions: 450-480 nm excitation filter (excf), 500 nm dichroic mirror (dm), and 515 nm barrier filter (bf) for Alexa 488; 330-385 nm excf, 400 nm dm, and 420 nm bf, for Hoechst 33342.

Images were recorded with a QICAM Fast 1394 Digital Camera (QImaging, Surrey, BC, Canada) and processed with Image-Pro Plus software (Media Cybernetics, Inc., Rockville, MD, USA).

The mean  $\pm$  standard error (SE) values of the analysed variables were calculated for each experimental condition, and statistical comparisons were performed by the one-way Anova test (statistical significance was set at  $p \leq 0.05$ ).


### Scanning electron microscopy

For SEM analysis,  $7 \times 10^4$  cells per well were seeded on slides of 12 mm in diameter. After 2 h and 24 h from the scratching, the cells were fixed in 4% paraformaldehyde in PBS for 2 h at 4°C, washed in the same buffer, post-fixed with 1%  $\text{OsO}_4$  at 4°C for 1 h, and dehydrated with acetone (Sigma-Aldrich). The samples were then treated by critical point dryer (CPD 030, Balzers), mounted on metallic specimen stubs and sputter-coated with gold (MED 010 Balzers). SEM imaging was performed by an XL30 ESEM (FEI-Philips). SEM images were used to perform quantitative evaluation of cell size and roughness. By using ImageJ software (NIH), the surface area of 50 cells per sample was measured; moreover, the cell surface facing the wound edge was measured both including and excluding cell protrusions in 10 cells per sample, the ratio between the two values was then calculated in order to obtain an index of cell surface irregularity (the higher the value the rougher the cell). Statistical evaluation of the results was performed by the one-way Anova.


### Atomic force microscopy

For AFM analysis,  $7 \times 10^4$  cells per well were seeded on slides of 12 mm in diameter. For topographic images at AFM, 2 h and 24 h post-treatment the cells were fixed in 2% glutaraldehyde in phosphate buffer for 20 min, washed in the same buffer and deposited onto 20 mm mica discs (Ted Pella Inc., Redding, CA, USA), after having dried the surfaces of the slides. The mica discs were mounted on suited metallic specimen discs in order to be

analysed with a NT-MDT Solver-pro equipped with a  $60 \times 60\text{-}\mu\text{m}$  scanner and gold-coated NSG-01 silicon probes, from the same company, with a curvature radius of 10 nm. To evaluate the cell thickness, the height profile was measured in 5 points (2 in the peripheral and 3 in the central region of the cell) along a line ( $n=25$  for each experimental condition). Height values were pooled according to the different experimental conditions, the mean  $\pm$  SE values were calculated and statistical comparison performed by the one-way Anova.




**Figure 1.** a) Inverted microscope images and (b) mean  $\pm$  SE values of cell-free areas of control (CTRL) and  $\text{O}_3$ -treated HeLa cells at different steps of the wound healing assays. Scale bars: 100  $\mu\text{m}$ .




**Figure 2.** Fluorescence microscopy images of control (a),  $\text{O}_3$  10  $\mu\text{g/mL}$  (b) and  $\text{O}_3$  35  $\mu\text{g/mL}$  (c) treated HeLa cells labelled for actin filaments (green). Control (d),  $\text{O}_3$  10  $\mu\text{g/mL}$  (e) and  $\text{O}_3$  35  $\mu\text{g/mL}$  (f) treated HeLa cells immunolabelled for BrdU (green). DNA was counterstained with Hoechst 33342 (blue). Scale bars: 20  $\mu\text{m}$ .





**Figure 3.** SEM images of control (a)  $O_3$  10  $\mu\text{g/mL}$  (b) and  $O_3$  35  $\mu\text{g/mL}$  (c) treated HeLa cells 24 h post wounding; insets: high magnification images of the dashed-line boxed areas; cell in interphase are flat with protruding microvilli, while mitotic cells (arrows) detach from the growth surface and become spherical in shape; scale bars: 25  $\mu\text{m}$ ; inset bars: 5  $\mu\text{m}$ . Mean  $\pm$  SE values of (d) cell area and (e) cell irregularity index at 2 h and 24 h from treatment; no statistical difference was found for both the cell area (2 h,  $P=0.605$ ; 24 h,  $P=0.687$ ) and irregularity index (2 h,  $P=0.850$ ; 24 h,  $P=0.673$ ).



**Figure 4.** Representative AFM images of control (a)  $O_3$  10  $\mu\text{g/mL}$  (b) and  $O_3$  35  $\mu\text{g/mL}$  (c) treated HeLa cells 2 h post treatment. d,e) Mean  $\pm$  SE values of cell height measured at AFM in control (CTRL) and in  $O_3$ -treated cells. The asterisk indicates statistical significance ( $P=0.002$ ), whereas no significant difference was found among samples for the peripheral region both after 2 h and 24 h ( $P=0.241$  and  $P=0.522$ , respectively), and for the central region after 24 h ( $P=0.565$ ).

## Results and Discussion

Cell movement plays a basic role in cell and tissue homeostasis as well as in many physiological and pathophysiological processes.<sup>41</sup> Altered regulation of cell motility is involved in several disorders, and migration of cancer cells is considered as a prerequisite for tumour metastasis.<sup>42</sup> Under our experimental conditions, the wound healing assay (Figure 1a) showed that the migration rates in control and O<sub>3</sub>-treated HeLa cells were similar at each time point considered (2 h, 6 h and 24 h) after gas exposure (Figure 1b).

In eukaryotic cells, reorganization of the cytoskeletal actin is the main responsible for cell shape modification and movement by driving the protrusions that push the membrane forward and lead to pseudopod extension.<sup>43</sup> After fluorescent phalloidin labelling, no evident changes in actin organization were observed in migrating cells at the wound edge after O<sub>3</sub> exposure compared to the controls (Figure 2 a-c). This is consistent with the observations at SEM that demonstrated an unchanged morphological pattern in control and O<sub>3</sub>-treated cells (Figure 3 a-c): in all samples, HeLa cells were flattened and irregularly polygonal in shape (apart from the sphere-shaped mitotic cells), and showed numerous filopodia and lamellipodia. The mean cell areas measured in SEM images were similar in the three experimental conditions at both 2 h and 24 h post-treatment (Figure 3d). Also the cell thickness at the peripheral and central region, as evaluated by AFM, was similar in control and O<sub>3</sub>-treated cells (with the only exception of the cells treated with O<sub>3</sub> 35 µg/mL after 2 h from gas exposure, that were transiently thicker than the controls in their central region) (Figure 4). Thus, O<sub>3</sub> treatment did not affect the volume of the cells along the wound edge, and quantitative evaluation of their surface roughness confirmed that also the surface protrusions did not significantly change (Figure 3e).

O<sub>3</sub> is a highly oxidizing gas and reactive oxygen species (ROS) are known to regulate cytoplasmic protrusions by controlling actin dynamics in a dose-dependent manner, high levels inducing protein depolymerization while low levels promoting polymerization.<sup>44-46</sup> Previous experiments<sup>39</sup> demonstrated that exposure to low O<sub>3</sub> concentrations causes a minimal ROS production, unable to induce structural or functional alterations in cell organelles including mitochondria. However, the O<sub>3</sub> effect on the polymerization of cytoskeletal proteins may depend on small local changes in ROS amounts. It could be therefore hypothesized that the higher oxidative stress caused by exposure to O<sub>3</sub> 35 µg/mL may induce a transient cytoskeletal remodelling that undergoes rapid restoration without affecting the cell periphery that is mainly involved in cell movement.

Recent findings<sup>47</sup> suggest that cell motility is affected also by Nrf2; in fact, its repressor factor Keap1 is involved in the disassembly of podosomes, known to promote cell motility and interactions;<sup>48</sup> however, Keap1 is unable to play its role when tethered to Nrf2. It is worth recalling that low O<sub>3</sub> concentrations induce an antioxidant response by the Keap1/Nrf2 dependent pathway,<sup>14</sup> thus releasing free Keap1 molecules in the cytoplasm. This could explain why Nrf2 was found to play an antitumour role by reducing cell migration.<sup>49-52</sup>

Tumour invasion not only depends on the cell migration ability, but also on the cell proliferation rate. In previous studies, we demonstrated that exposure to low O<sub>3</sub> concentrations does not change both death rate<sup>14,39</sup> and proliferation rate of subconfluent HeLa cells<sup>39</sup> as well as of other cancer cell lines.<sup>53</sup> The present study shows that mild exposure to O<sub>3</sub> does not alter the percentage of BrdU-positive cells (26.92±1.47%, n=1915 in controls; 27.59±1.32%, n=1928 in cells treated with O<sub>3</sub> 10 µg/mL ;

25.81±1.36%, n=1871 in cells treated with O<sub>3</sub> 35 µg/mL ; P=0.690) or the mitotic index (5.13±1.17% in controls, 5.81±1.05% in cells treated with O<sub>3</sub> 10 µg/mL, and 4.62±1.23% in cells treated with O<sub>3</sub> 35 µg/mL ; P=0.657) along the wound edge (Figure 2 d-f). These findings provide evidence that the exposure to low O<sub>3</sub> concentrations leaves unchanged the *in vitro* cell proliferation not only in sub-confluent populations but also during wound healing, *i.e.*, in a growth-stimulating condition.

In conclusion, the low O<sub>3</sub> concentrations used under *in vitro* conditions in our study proved not to alter cytomorphology, migration features or cell proliferation of HeLa cells during wound healing, thus supporting the notion that O<sub>3</sub> therapy should not positively affect tumour cell growth and metastasis. Especially due to the multiple indirect effects of O<sub>3</sub> in a living organism, the *in vivo* conditions are obviously much more complex than those of an *in vitro* model; thus, further studies are needed to clarify the consequences of the exposure to low O<sub>3</sub> concentrations in tumour-bearing organisms, with particular reference to the possible interference with chemotherapeutics.<sup>36</sup>

## Acknowledgements

*This work was supported by the University of Verona (Joint Projects 2017).*

## References

1. Viebahn-Hänsler R, León Fernández OS, Fahmy Z. Ozone in medicine: The low dose ozone concept-guidelines and treatment strategies. *Ozone Sci Eng* 2012;34:408-24.
2. Galìè M, Covi V, Tabaracci G, Malatesta M. The role of Nrf2 in the antioxidant cellular response to medical ozone exposure. *Int J Mol Sci* 2019;20 pii:E4009.
3. Bocci VA, Zanardi I, Travagli V. Ozone acting on human blood yields a hormetic dose-response relationship. *J Transl Med* 2011;9:66.
4. Sagai M, Bocci V. Mechanisms of action involved in ozone therapy: is healing induced via a mild oxidative stress? *Med Gas Res* 2011;1:29.
5. Goldman M. Cancer risk of low-level exposure. *Science* 1996;271:1821-2.
6. Furukawa M, Xiong Y. BTB protein Keap1 targets antioxidant transcription factor Nrf2 for ubiquitination by the Cullin 3-Roc1 ligase. *Mol Cell Biol* 2005;25:162-71.
7. Pecorelli A, Bocci V, Acquaviva A, Belmonte G, Gardi C, Virgili F, et al. NRF2 activation is involved in ozonated human serum upregulation of HO-1 in endothelial cells. *Toxicol Appl Pharmacol* 2013;267:30-40.
8. Re L, Martínez-Sánchez G, Bordicchia M, Malcangi G, Pocognoli A, Morales-Segura MA, et al. Is ozone pre-conditioning effect linked to Nrf2/EpRE activation pathway *in vivo*? A preliminary result. *Eur J Pharmacol* 2014;742:158-62.
9. Valacchi G, Sticozzi C, Zanardi I, Belmonte G, Cervellati F, Bocci V, et al. Ozone mediators effect on "in vitro" scratch wound closure. *Free Radic Res* 2016;50:1022-31.
10. Delgado-Roche L, Riera-Romo M, Mesta F, Hernández-Matos Y, Barrios JM, Martínez-Sánchez G, et al. Medical ozone promotes Nrf2 phosphorylation reducing oxidative stress and pro-inflammatory cytokines in multiple sclerosis patients. *Eur J Pharmacol* 2017;811:148-54.
11. Meng W, Xu Y, Li D, Zhu E, Deng L, Liu Z, et al. Ozone pro-



- fects rat heart against ischemia-reperfusion injury: a role for oxidative preconditioning in attenuating mitochondrial injury. *Biomed Pharmacother* 2017;88:1090-97.
12. Wang Z, Zhang A, Meng W, Wang T, Li D, Liu Z, et al. Ozone protects the rat lung from ischemia-reperfusion injury by attenuating NLRP3-mediated inflammation, enhancing Nrf2 antioxidant activity and inhibiting apoptosis. *Eur J Pharmacol* 2018;835:82-93.
  13. Braidy N, Izadi M, Sureda A, Jonaidi-Jafari N, Banki A, Nabavi SF, et al. Therapeutic relevance of ozone therapy in degenerative diseases: Focus on diabetes and spinal pain. *J Cell Physiol* 2018;233:2705-14.
  14. Galiè M, Costanzo M, Nodari A, Boschi F, Calderan L, Mannucci S, et al. Mild ozonisation activates antioxidant cell response by the Keap1/Nrf2 dependent pathway. *Free Radic Biol Med* 2018;124:114-21.
  15. Borrelli E. Mechanism of action of oxygen ozone therapy in the treatment of disc herniation and low back pain. *Acta Neurochir Suppl* 2011;108:123-5.
  16. Muto M, Giurazza F, Silva RP, Guarnieri G. Rational approach, technique and selection criteria treating lumbar disk herniations by oxygen-ozone therapy. *Interv Neuroradiol* 2016;22:736-40.
  17. Lopes de Jesus CC, Dos Santos FC, de Jesus LMOB, Monteiro I, Sant'Ana MSSC, Trevisani VFM. Comparison between intra-articular ozone and placebo in the treatment of knee osteoarthritis: A randomized, double-blinded, placebo-controlled study. *PLoS One* 2017;12:e0179185.
  18. Carpendale MT, Freeberg J, Griss JM. Does ozone alleviate AIDS diarrhea? *J Clin Gastroenterol* 1993;17:142-5.
  19. Altinel O, Demirbas S, Cakir E, Yaman H, Ozerhan I.H, Duran E, et al. Comparison of hyperbaric oxygen and medical ozone therapies in a rat model of experimental distal colitis. *Scand J Clin Lab Invest* 2011;71:185-92.
  20. Aslaner A, Çakır T, Tekeli S, Avcı S, Doğan U, Tekeli F, et al. Medical ozone treatment ameliorates the acute distal colitis in rat. *Acta Cir Bras* 2016;31:256-63.
  21. Hernández Rosales FA, Calunga Fernández JL, Turrent Figueras J, Menéndez Cepero S, Montenegro Perdomo A. Ozone therapy effects on biomarkers and lung function in asthma. *Arch Med Res* 2005;36:549-54.
  22. Kucukgul A, Erdogan S, Gonenci R, Ozan G. Beneficial effects of nontoxic ozone on H<sub>2</sub>O<sub>2</sub>-induced stress and inflammation. *Biochem Cell Biol* 2016;94:577-83.
  23. Gupta G, Mansi B. Ozone therapy in periodontics. *J Med Life* 2012;5:59-67.
  24. Al-Omiri, MK, Abul Hassan RS, AlZarea BK, Lynch E. Comparison of dental bleaching effects of ozone and hydrogen peroxide: An ex vivo study. *Am J Dent* 2016;29:251-4.
  25. Isler SC, Unsal B, Soysal F, Ozcan G, Peker E, Karaca IR. The effects of ozone therapy as an adjunct to the surgical treatment of peri-implantitis. *J Periodontal Implant Sci* 2018;48:136-51.
  26. Petrucci MT, Gallucci C, Agrillo A, Mustazza MC, Foà R. Role of ozone therapy in the treatment of osteonecrosis of the jaws in multiple myeloma patients. *Haematologica* 2007;92:1289-90.
  27. Berni F, Bolletini A, Bonfatti A, Chiamenti L, De Belardini V, De Bonis T, et al. Effectiveness of oxygen-ozone therapy as support treatment in the care of cancer patients undergoing chemo/radiotherapy (Conference Paper). *Int J Ozone Ther* 2013;12:38-9.
  28. Clavo B, Santana-Rodríguez N, Llontop P, Gutierrez D, Ceballos D, Méndez C, et al. Ozone therapy in the management of persistent radiation-induced rectal bleeding in prostate cancer patients. *Evid Based Complement Alternat Med* 2015;2015:480369.
  29. Velikaya VV, Gribova OV, Musabaevau U, Startseva ZhA, Simonov KA, Aleinik AN, et al. Ozone therapy for radiation reactions and skin lesions after neutron therapy in patients with malignant tumors. *Voprosy Onkologii* 2015;61:571-4.
  30. Luongo M, Brigida AL, Mascolo L, Gaudino G. Possible therapeutic effects of ozone mixture on hypoxia in tumor development. *Anticancer Res* 2017;37:425-35.
  31. DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. *Nature* 2011;475:106-9.
  32. Mitsuishi Y, Taguchi K, Kawatani Y, Shibata T, Nukiwa T, Aburatani H, et al. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. *Cancer Cell* 2012;22:66-79.
  33. Chio II, Jafarnejad SM, Ponz-Sarvisé M, Park Y, Rivera K, Palm W, et al. NRF2 promotes tumor maintenance by modulating mRNA translation in pancreatic cancer. *Cell* 2016;166:963-76.
  34. Hojo T, Maishi N, Towfik AM, Akiyama K, Ohga N, Shindoh M, et al. ROS enhance angiogenic properties via regulation of NRF2 in tumor endothelial cells. *Oncotarget* 2017; 8:45484-95.
  35. Kang KA, Hyun JW. Oxidative stress, Nrf2, and epigenetic modification contribute to anticancer drug resistance. *Toxicol Res* 2017; 33:1-5.
  36. Clavo B, Santana-Rodríguez N, Llontop P, Gutiérrez D, Suárez G, López L, et al. Ozone therapy as adjuvant for cancer treatment: Is further research warranted? *Evid Based Complement Alternat Med* 2018;2018:7931849.
  37. Tirelli U, Cirrito C, Pavanello M, Del Pup L, Lleshi A, Berretta M. Oxygen-ozone therapy as support and palliative therapy in 50 cancer patients with fatigue - A short report. *Eur Rev Med Pharmacol Sci* 2018;22:8030-3.
  38. Jonkman JEN, Cathcart JA, Xu F, Bartolini ME, Amon JE, Stevens KM, et al. An introduction to the wound healing assay using live-cell microscopy. *Cell Adh Migr* 2014;8:440-51.
  39. Costanzo M, Cisterna B, Vella A, Cestari T, Covi V, Tabaracci G, et al. Low ozone concentrations stimulate cytoskeletal organization, mitochondrial activity and nuclear transcription. *Eur J Histochem* 2015;59:2515.
  40. Costanzo M, Cisterna B, Covi V, Tabaracci G, Malatesta M. An easy and inexpensive method to expose adhering cultured cells to ozonization. *Microscopie* 2015;23:46-52. Available from: <https://www.pagepressjournals.org/index.php/microscopie/article/view/5164>
  41. Ridley AJ, Schwartz MA, Burridge K, Firtel RA, Ginsberg MH, Gary Borisy G, et al. Cell Migration: Integrating Signals from Front to Back. *Science* 2003;302:1704-9.
  42. Fife CM, McCarroll JA, Kavallaris M. Movers and shakers: cell cytoskeleton in cancer metastasis. *Br J Pharmacol* 2014;171:5507-23.
  43. Huang CH, Tang M, Shi C, Iglesias PA, Devreotes PN. An excitable signal integrator couples to an idling cytoskeletal oscillator to drive cell migration. *Nat Cell Biol* 2013;15:1307-16.
  44. Sakai J, Li J, Subramanian KK, Mondal S, Bajrami B, Hattori H, et al. Reactive oxygen species (ROS)-induced actin glutathionylation controls actin dynamics in neutrophils. *Immunity* 2012;37:1037-49.
  45. Taulet N, Delorme-Walker VD, DerMardirossian C. Reactive oxygen species regulate protrusion efficiency by controlling actin dynamics. *PLoS ONE* 2012;7:e41342.
  46. Mulyiyil S, Narasimha M. Mitochondrial ROS regulates cytoskeletal and mitochondrial remodeling to tune cell and tissue dynamics in a model for wound healing. *Dev Cell* 2014;28:239-52.
  47. Kloska D, Kopacz A, Cysewski D, Aepfelbacher M, Dulak J,

- Jozkowicz A, et al. Nrf2 sequesters Keap1 preventing podosome disassembly: a quintessential duet moonlights in endothelium. *Antioxid Redox Signal* 2019;30:1709-30.
48. Paterson EK, Courtneidge SA. Invadosomes are coming: new insights into function and disease relevance. *FEBS J* 2018;285:8-27.
49. Rachakonda G, Sekhar KR, Jowhar D, Samson PC, Wikswo JP, Beauchamp RD, et al. Increased cell migration and plasticity in Nrf2-deficient cancer cell lines. *Oncogene* 2010;29:3703-14.
50. Chien MH, Lee WJ, Hsieh FK, Li CF, Cheng TY, Wang MY, et al. Keap1-Nrf2 interaction suppresses cell motility in lung adenocarcinomas by targeting the s100p protein. *Clin Cancer Res* 2015;21:4719-32.
51. Tertilt M, Golda S, Skrzypek K, Florczyk U, Weglarczyk K, Kotlinowski J, et al. Nrf2-heme oxygenase-1 axis in mucoepidermoid carcinoma of the lung: antitumoral effects associated with down-regulation of matrix metalloproteinases. *Free Radic Biol Med* 2015;89:147-57.
52. Xue D, Zhou C, Shi Y, Lu H, Xu R, He X. Nuclear transcription factor Nrf2 suppresses prostate cancer cells growth and migration through upregulating ferroportin. *Oncotarget* 2016;7:78804-12.
53. Scassellati C, Costanzo M, Cisterna B, Nodari A, Galiè M, Cattaneo A, et al. Effects of mild ozonisation on gene expression and nuclear domains organization in vitro. *Toxicol In Vitro* 2017;44:100-10.

Non-commercial use only

---

Received for publication: 23 February 2020. Accepted for publication: 19 March 2020.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).

©Copyright: the Author(s), 2020

Licensee PAGEPress, Italy

*European Journal of Histochemistry* 2020; 64:3119

doi:10.4081/ejh.2020.3119